Fair enough. One of the focus areas for our industry has been trying to work within the Codex system to come up with a more robust international reference point for setting these tolerances. A large majority of the countries that we export pulses to are countries that don't have the kind of regulatory capacity that Canada has. Consequently, they don't have a PMRA, they use Codex, the World Health Organization, to set their tolerances.
The more countries we see moving towards their own custom national approaches, the greater the need to make sure that we have a functioning Codex, which has some capacity problems. We're trying to work internationally, and PMRA has shown great leadership in trying to make sure that they have fewer delays.
In general, it's a challenging problem. There are two problems that I think we've touched on today. One is the lack of harmonized tolerances when regulators go through the process of doing the risk assessments. That might become serious for our industry someday, but it's not today. It's really the absence of tolerances, so it's the lack of harmonized timing and the zero, or near zero, tolerances that we could be subject to in a parts per trillion environment.